Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

Healthcare Drug Manufacturers - Specialty & Generic
"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

MERUS LABS INTERNATIONAL INC > Featured in Globe & Mail - msl and CRH
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by curiousbuildon Sep 22, 2015 2:16pm
90 Views
Post# 24125816

RE:RE:RE:RE:RE:RE:Featured in Globe & Mail - msl and CRH

RE:RE:RE:RE:RE:RE:Featured in Globe & Mail - msl and CRH
seems pretty relevant to sheeps that follow mass opinions since his fund only owned 0.024% of the company proabably.. I wonder if his fund went from $30M+ to around $26M last few months.. what went wrong?

Happy money making

CB
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities